AAIT is an acronym for autologous adoptive immune therapy and defines a therapy derived from a patient's own blood, which is re-infused during cancer treatment. There are abundant strategies for immunotherapy (免疫療法 )and just as many treatments that can be referenced as autologous adoptive immunotherapy.€ Clearly, not all options are deemed comparable.

Lymphocytes immunotherapy, AAIT, involves 4 major cell types which include Natural killer cells Natural killer T cells, Cytokine-induced killer cells, Cytotoxic T lymphocytes - where the inclusion of Natural killer cells (NKs) and Natural killer T cells (NKTs) are the predominant focus of Lymphocytes immunotherapy serums.

Natural Killer Cells Important in Cancer Prognosis of Cancer

When NK cell numbers and functionality are low, cancer patients are predisposed to more aggressive tumor growth. And, as disease progresses, such declines are likely to continue. In both animal and human clinical trials, we have seen that by restoring NK and NKT function leads to enhanced cellular immune tumor-response and higher patient survival rates.

Keys to Lymphocytes Immunotherapy (免疫治療 ) Uniqueness

1) Lymphocytes protocol for AAIT immunotherapy is designed to optimize the expansion of natural killer cells - the most potent cancer fighting component of the cellular immune system. Most immunotherapy treatments do not include natural killer cells, and those that do only expand them in low numbers with little activation. (がん治療 )

2) Lymphocytes immunotherapy protocol takes only 4-5 weeks to grow your cells, so you can begin to experience benefits quickly. Moreover, while other immune therapies administer just 100-200 million cells per treatment, Envita delivers roughly 100 times as many during the course of your treatment. (乳がん )

3) Multitudes of published studies demonstrate the effects of adoptive immunotherapy for cancer patients among which Envita has identified and improved upon the best. Company protocol insists upon the highest-level of procedure for the expansion and application of cells for each immunotherapy treatment. (前立腺がん )

4) Unlike other published immune therapies, Lymphocytes is the only one that can be used as a €stand-alone.€ Moreover, it may also be administered in conjunction with other therapies to enhance the cells' effects in patients - an incomparable benefit. Lymphocytes immunotherapy is not focused solely on expanding cells in the lab; rather, our goal also includes keeping them active until reintroduced to the patient's body.

5) Lymphocytes immunotherapy vaccine offers far greater tumor kill, or cytotoxicity than that of other well-regarded cancer cell vaccines / immunotherapy treatments found throughout the world. In brief, this means Lymphocytes activated natural killer cells in AAIT immunotherapy deliver considerably higher tumor obliteration.

6) In summary, the most direct manner to stack Lymphocytes proprietary immunotherapy against the others includes its:

a. Quality - based on cytoxicity (how much tumor the immune system can kill). Lymphocytes immunotherapy consistently delivers €significantly greater tumor kill€.

b. Quantity (how many cells you get back) - Lymphocytes immunotherapy comes with 100 times the cell dosage than the others.

c. Sterility (quality control measures) - Envita AAIT immunotherapy is completely contaminant free.

If you have any questions concerning Lymphocytes immunotherapy, please consult with Lymphocytes team of physicians and patient educators. This immunotherapy is offered at Lymphocytes international cancer center in Japan. for more information (http://www.lymphocyte-bank.co.jp/ )